Modern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf
Thamer Alessa,Fatheya Al Awadi,Juma Al Kaabi,Ali Al Mamari,Ebaa Al Ozairi,Dalal Alromaihi,Tarik Elhadd,Abdallah Gunaid,Mohamed Hassanein,Amin Jayyousi,Raya Kalimat,Kerstin Brand
DOI: https://doi.org/10.2147/dmso.s491591
2024-12-18
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Thamer Alessa, 1 Fatheya Al Awadi, 2 Juma Al Kaabi, 3 Ali Al Mamari, 4 Ebaa Al Ozairi, 5 Dalal Alromaihi, 6 Tarik Elhadd, 7 Abdallah A Gunaid, 8 Mohamed Hassanein, 9 Amin A Jayyousi, 10 Raya Kalimat, 11 Kerstin MG Brand 12 1 Division of Endocrinology, Jaber Al-Ahmad Hospital, Kuwait City, Kuwait; 2 Endocrine Department, Dubai Hospital, Dubai Academic Health Corporation (DAHC), Dubai, United Arab Emirates; 3 Department of Internal Medicine, College of Medicine and Health Sciences, The United Arab Emirates University, Al-Ain, United Arab Emirates; 4 Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman; 5 Clinical Research Unit, Dasman Diabetes Institute, Dasman, Kuwait; 6 Internal Medicine Department, Royal College of Surgeons in Ireland-Medical University of Bahrain, Adliya, Kingdom of Bahrain; 7 Endocrine Section, Department of Medicine, Hamad Medical Corporation, Doha, Qatar; 8 Internal Medicine, Sana'a University Faculty of Medicine, Sanaa, Yemen; 9 Department of Endocrinology and Diabetes, Dubai Hospital, Dubai Academic Health Corporation (DAHC), Dubai, United Arab Emirates; 10 Department of Endocrinology, Hamad Medical Corporation, Doha, Qatar; 11 Medical Affairs, Merck Serono Middle East FZ-LLC, Dubai, United Arab Emirates; 12 Global Research & Development Medical – MU CM&E, Merck Healthcare KGaA, Darmstadt, Germany Correspondence: Thamer Alessa, Division of Endocrinology, Jaber Al-Ahmad hospital, South Surra, Ministries Area, Kuwait City, 13060, Kuwait, Email Prediabetes is the first stage of a continuum that extends through the diagnosis of clinical type 2 diabetes towards long-standing diabetes with multiple comorbidities. The diagnosis of prediabetes provides an opportunity to interrupt the diabetes continuum at an early stage to ensure long-term optimization of clinical outcomes. All people with prediabetes should receive intervention to improve their lifestyles (quality of diet and level of physical activity), as this has been proven beyond doubt to reduce substantially the risk of conversion to diabetes. Additionally, a large base of clinical evidence supports the use of metformin in preventing or delaying the transition from prediabetes to clinical type 2 diabetes, for some people with prediabetes. For many years, guidelines for the management of type 2 diabetes focused on lowering blood glucose, with metformin prescribed first for those without contraindications. More recently, guidelines have shifted towards prevention of diabetes complications as the primary goal, with increased use of GLP-1 receptor agonists (or multi-agonist incretin peptides) or SGLT-2 inhibitors for patients with existing atherosclerotic cardiovascular disease, heart failure or chronic kidney disease. Access to these medications often remains challenging. Metformin remains a suitable option for initial pharmacologic intervention to manage glycemia for many people with prediabetes or type 2 diabetes along with other therapy to maintain control of blood glucose or to address specific comorbidities as the patient progresses along the diabetes continuum. Keywords: type 2 diabetes, prediabetes, diabetes continuum, metformin, antidiabetic therapy, diabetes complications The landscape of diabetes has changed dramatically in recent times, with a substantial proportion of the population with, or at short-term risk of developing type 2 diabetes: a recent survey covering 204 countries estimated that 529 million people were living with diabetes in 2021 (96% of these people have type 2 diabetes), a number projected to increase to 1.3 billion by the year 2050. 1 Complications of diabetes relate to the microvascular system (eg nephropathy, neuropathy, diabetic foot) and the macrovascular system (atherosclerosis, increased risk of major adverse cardiovascular outcomes such as myocardial infarction, heart failure, stroke). 2 Moreover, the pathogenesis of diabetes complications begins for many people long before a clinical diagnosis of diabetes. 3–6 Indeed, prediabetes and diabetes exist within a continuum, from the earliest adverse metabolic changes associated with insulin resistance and subsequent β-cell dysfunction, through the initial diagnosis of type 2 diabetes, to the familiar complications of long-standing type 2 diabetes. 7 The increasing challenge of addressing the adverse consequences of the diabetes continuum has been accompanied by a large increase in the choice of antihyperglycaemic treatments in recent years. While the options for personalized medicine for people with type 2 diabetes are greater than ever, designi -Abstract Truncated-
endocrinology & metabolism